News Release

Steroids during surgery may not be helpful for infants having heart bypass

American Heart Association Scientific Sessions 2022, Control 18658

Reports and Proceedings

American Heart Association

Embargoed until 8:13 a.m. CT/9:13 a.m. ET, Sunday, Nov. 6, 2022

CHICAGO, Nov. 6, 2022 — The largest clinical trial ever conducted in infants younger than age 1 undergoing heart surgery with cardiopulmonary bypass found that administering steroids during surgery did not improve post-operative outcomes compared to placebo, according to preliminary late-breaking research to be presented at the American Heart Association’s Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov. 5-7, 2022, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

According to the American Heart Association’s 2022 Heart Disease & Stroke Statistical Update, approximately 40,000 children in the U.S. every year undergo heart surgery to treat congenital heart defects. Despite major medical advances, congenital heart disease requiring surgery during infancy is still considered high risk with potential for complications, including neurological injuries, respiratory failure with need for tracheostomy, cardiac arrest or the need for machines to assist with blood circulation and oxygenation after surgery. These outcomes are often associated with severe systemic inflammatory responses, which may contribute to worse post-operative outcomes.

“In an effort to reduce this inflammatory reaction and to improve post-operative outcomes, some health care professionals administer steroids during surgery, while others believe that the side effects of steroids outweigh the benefits,” said lead study author Kevin D. Hill, M.D., M.S., a professor of pediatrics at Duke University Pediatric and Congenital Heart Center in Durham, North Carolina.

Previous studies have found wide variability among clinicians, with some routinely administering steroids during infant heart surgery, some routinely avoiding steroids and others employing a selective approach depending on the complexity of the case and the patient’s age.

“Professionals have been debating the use of steroids during infant heart surgery for decades with relatively little evidence to support their safety or effectiveness,” Hill said. “Due to the difficulties in enrolling children in clinical trials, there have been only three randomized, controlled trials of steroid use in infants with heart disease reported over the past five years, and the results are conflicting.”

Researchers examined data from the Society of Thoracic Surgeons Congenital Heart Surgery Database to evaluate the safety and effectiveness of steroids in infants younger than 12 months of age undergoing heart surgery. The STeroids to Reduce Systemic inflammation after infant heart Surgery (STRESS) Trial compared the administration of steroids at initiation of cardiopulmonary bypass vs. placebo on combined clinical outcomes, including post-operative complications, hospital length of stay and mortality. They also compared individual outcomes in a secondary analysis.

This study was conducted at 24 centers across the U.S., and a total of 1,200 infants were enrolled, representing the largest trial ever conducted in children undergoing heart surgery. Approximately half of the patients were female, 16% were Black infants and 12% were Hispanic children, “which is representative of the U.S. population of children undergoing heart surgery,” Hill said. The average age at the time of surgery was four months, and more than 30% of patients were younger than 30 days old at the time of surgery.

After obtaining informed consent from parents, half of the infants were randomly assigned to receive a single dose of steroids during surgery while the other half received a placebo. The primary analysis of the results, after adjusting for baseline characteristics, showed no significant difference in post-operative outcomes between those receiving steroids or placebo.

The secondary analysis found that patients receiving steroids had lower odds of bleeding requiring another operation.

“When we analyzed the primary endpoint using a different approach known as the ‘win ratio,’ there was evidence that steroids provided a small net benefit,” Hill said, but other outcomes were comparable for the two groups including mortality, post-operative infections and the need for mechanical ventilation and length of hospital stay:

  • The mortality rate among the infants who received steroids was 2.0% compared to 2.8% in the placebo group.
  • The rate of mortality or major post-operative complications combined was 17.2% for the steroid group vs. 20.3% of those in the placebo group.
  • Post-operative infection complications occurred in 5.2% of those who received steroids compared to 4% of the placebo group.
  • 6.8% of the steroid group needed prolonged mechanical ventilation compared to 8.5% of the placebo group.
  • The average hospital length of stay for infants who received steroids was 10 days, compared to 11 days for those in the placebo group.
  • Infants in the steroid group were more likely to have high blood sugar, which is a known side effect of steroids, with 19% of infants requiring insulin within 24 hours of surgery. In comparison, 6.7% of the infants in the placebo group required insulin within 24 hours of surgery.

The investigators’ review of all outcome components concludes that steroid administration may hold a small benefit for some infants.

“Although our primary analysis did not find a difference in outcomes for those treated with steroids, there were enough secondary signals indicating a benefit that the consensus of our investigative team, including multiple pediatric cardiologists and congenital heart surgeons, is that steroids may offer a small benefit,” Hill said.

“Every day, clinical decisions have to be made, and for infants needing heart surgery, there may not be sufficient evidence to support the treatments.  There is a need for more studies to determine the optimal dose and to evaluate which children might benefit more than others,” he added. “There is also a need to evaluate whether lower doses of steroids may offer similar benefits but with less risk of hyperglycemia.”

The study’s limitations included that more than a quarter of the trial participants were administered steroids after surgery, more commonly among those in the placebo group. “This may have masked some of the effectiveness of prophylactic steroids,” Hill said.

Co-authors are Prince J. Kannankeril, M.D., M.S.C.I.; Jeffrey P. Jacobs, M.D.; H. Scott Baldwin, M.D.; Marshall L. Jacobs, M.D.; Sean M. O’Brien, Ph.D.; David P. Bichel, M.D.; Eric M. Graham, M.D., FAHA; Brian Blasiole, M.D., Ph.D.; Ashraf Resheidat, M.D.; Adil S. Husain, M.D.; Ram Kumar Subramanyan, M.D., Ph.D.; Soju Chang, M.D., M.P.H.; Jerry L. Kirchner, B.S., CCRP; Dianne S. Gallup, M.S.; Joseph W. Turek, M.D., Ph.D.; Mark Bleiweis, M.D.; Bret Mettler, M.D.; Alexis Benscoter, M.D.; Eric Wald, M.D.; Tara Karamlou, M.D., M.Sc.; Andrew H. Van Bergen, M.D.; David Overman, M.D.; Pirooz Eghtesady, M.D., FAHA; Ryan Butts, M.D.; John S. Kim, M.D.; John P. Scott, M.D.; Brett R. Anderson, M.D., M.B.A., M.S.; Michael F. Swartz, Ph.D.; Patrick I. McConnell, M.D.; and Jennifer S. Li, M.D., M.H.S. Authors’ disclosures are listed in the abstract.

The study was funded by the National Institutes of Health (NIH), the National Centers for Advancing Translational Sciences, a division of NIH, and the Pediatric Trials Network (National Institutes for Child Health and Development).

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

Additional Resources:

The American Heart Association’s Scientific Sessions 2022 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates occurring Saturday through Monday, November 5-7, 2022. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2022 on social media via #AHA22. 

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.  

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.